Background: Mycobacterium tuberculosis (TB) and Human Immunodefi ciency Virus (HIV) infections are two major public health problems in many parts of the world, particularly in developing counties like Nepal. The objective of the study is to fi nd out prevalence and clinical presentation of the TB co-infection among HIV infected individuals and pattern of CD4 cell count in relation to types of TB and response of ART.
INTRODUCTION
The United Nations Joint Programme on HIV/AIDS (UNAIDS, 2009) report estimated that 33.4 million people are living with Human Immunodefi ciency Virus (HIV) in worldwide, and one third of them are co-infected with tuberculosis (TB). HIV infection increases susceptibility to TB and is the most potent factor in transferring latent or recently acquired TB infection to active clinical diseases. In addition, TB in high HIV prevalence populations is a leading cause of morbidity and mortality. TB patients have been suggested to be an important population for fi nding of HIV infections. Therefore, prevention and control of co-infection is vital to reduce the epidemic of TB and HIV/ AIDS. pediatric deaths. 2 In infants and young children, immune system immaturity and high viral loads lead to a high risk of rapid disease progression. 3 Since the detection of the fi rst AIDS case in 1988, the HIV epidemic in Nepal has evolved from a low prevalence to concentrated epidemic. As of 2009, national estimates indicate that approximately 63,528 adults and children are infected with the HIV virus in Nepal, with an estimated prevalence of about 0.39% in the adult population. 4 Mycobacterium tuberculosis and human immune defi ciency virus infections are two major public health problems in many parts of the world, particularly in many developing counties.
1 Coinfection with HIV may worsen the course and complicate the diagnosis and management of TB. Overall, HIV-infected patients have 60% higher risk of acquiring TB in comparison to 10% in non HIV group and this risk remains elevated throughout the course of HIV disease. 5 Prompt diagnosis and treatment are essential to improve drug-resistant TB outcomes, but TB diagnosis in patients with HIV co-infection is challenging, particularly in resource-limited settings. HIV-infected TB patients have higher rates of extra-pulmonary disease, atypical clinical presentations, and normal chest radiographs. 6 Tuberculosis and HIV control programmes clearly have mutual concerns: the prevention of HIV infection and the treatment of HIV/AIDS should be components of tuberculosis control, and tuberculosis care and prevention should be priorities in the management of HIV/AIDS. 7 TB is the most frequent life-threatening opportunistic disease among people living with HIV and remains a leading cause of mortality, even among persons receiving antiretroviral therapy (ART). Clinical trials have shown that isoniazid preventive therapy (IPT) dramatically reduces the incidence of TB among people living with HIV. A 2004 Cochrane Review found that IPT reduced the risk of TB by 33% overall and by 64% when targeted to people living with HIV who had a positive tuberculin skin test. A recent retrospective study also showed that IPT signifi cantly reduced the incidence of TB even among people living with HIV and receiving ART. While the lifetime  risk of developing active TB is approximately 10%  for immune-competent persons following initial  infection, for persons with HIV co-infection the  annual risk can exceed 10%, and the risk of TB  reactivation rises as the CD4cell count declines.   2 HIV-infected persons are at risk of TB throughout their course of disease, even after they respond to ART. 9 In Nepal, the fi rst case was demonstrated in 1988 and the concept of treating HIV infection with highly active antiretroviral treatment (HAART) was introduced quite later.
10 Among those with HIV infection, the CD4+ T-lymphocyte count is the major indicator of immunodefi ciency, a main factor in deciding whether to initiate HAART, and an important parameter in monitoring treatment response. Despite current recommendations to start HAART at CD4+ counts of 350 cells/mm3 or greater, the reality is that many patients, even in developed countries, are still being diagnosed and initiate treatment late in the course of their HIV infection.
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Treatment of tuberculosis patients in resourcelimited countries with concurrent epidemics of Hepatitis C Virus (HCV), Hepatitis B Virus (HBV), and HIV may be associated with signifi cant hepatoxicity. Serologic screening of tuberculosis patients for HBV, HCV and HIV or using behavioral algorithms to identify patients in need of intensive monitoring during anti-tuberculosis therapy may reduce this risk. 12 The present study is focused to fi nd out prevalence of TB among HIV infected individuals, clinical features and ART response on CD 4 cell count.
METHODOLOGY

Setting:
The study was carried out in three different places viz. BPKIHS, Dharan; SPARSA Nepal, Kathmandu and Sukhra Raj Tropical and Infectious Disease Hospital, Teku, Kathmandu (TEKU Hospital) from April 2010 to March 2011. It was done with due privacy in their respective VCT Clinic by face to face interview with the HIV infected individuals based on pretested semistructured questionnaire. Also, an address was given to the past medical documents, for better authenticity of the information, which most of them had themselves.
Study subjects:
The target population of the study was the HIV infected persons visiting the VCT Clinic either for taking medications or for follow-up of regular check up during 1 year period. Among those who gave supportive consent, an approach was made to include all individuals whether they were already taking medications or about to start. A total of 313 HIV infected individuals were interviewed.
Study design and sample size: This is a cross sectional, descriptive study which includes primary and secondary data. Based on the prevalence of TB co-infection among HIV individuals (33.3%) 1 , the required sample size was calculated as 315 based on the precision of 5.33 (16% of prevalence) at 95% confi dence limit after adding 5% for nonresponse. Two individuals disagreed to participate in the study.
Exclusion criteria:
Those who didn't give consent and who couldn't report CD 4 count were excluded. The CD 4 count was done by the patients themselves.
Statistical analysis:
The data was entered into Microsoft Excel 2007 and analyzed in SPSS 17.0. Mean, median and standard deviation were calculated. Mann-Whitney Test and Chi square test were applied to fi nd out statistical signifi cance in numeric and categorical data respectively. Probability of signifi cance was set at 5% level of signifi cance. Odds Ratio (OR) and its 95% confi dence interval (CI) were also calculated to examine strength of association between the categorical variables and its' limit.
Ethical consideration: Ethical consent was taken from institutional review board BPKIHS, Dharan; SPARSA NEPAL, Kathmandu and Sukhra Raj Tropical and Infectious Disease Hospital (Teku, Kathmandu). Verbal consent was also taken with the individuals who were diagnosed to be HIV infected prior to interview. Privacy of participants was maintained during interview with due consideration of the emotional aspect.
The normal oral or ear temperature is 37˚ C but may range between 35.8˚C and 37.2˚C. 13 The temperature more than this was considered to be fever. Diarrhea was defi ned as 2 or more loose or watery stools per day for more than 2 consecutive days.
14 Chronic diarrhea was defi ned as diarrhea persisting for more than 14 days. 15 Tuberculosis coinfection was ascertained by past medical records and history of taking anti-tubercular therapy. HBV and HCV infection were considered positive with respect to serological tests as per medical records. Individuals who gave history of use of syringes for self administration of drugs were considered intravenous drug users (IDU). Most of IDU, but not all, had multiple scar marks on their forearm. The threshold for starting ART was considered to be CD 4 count to be less than 250/μL. Weight loss may be due to lack of food intake (anorexia, dysphasia or vomiting), mal-absorption of nutrients, or a systemic effect of important diseases such as cancer (within or outside the gastrointestinal tract), infl ammatory bowel disease or chronic infections such as TB (within or outside the gastrointestinal tract). 16 Weight loss in HIV infected patients can be due to HIV wasting syndrome or due to chronic infections like tuberculosis. HIV wasting syndrome has been defi ned by the Centre for Disease Control (CDC), USA, as involuntary weight loss greater than 10% of baseline weight associated with either chronic diarrhea for at least 30 days or chronic weakness or documented fever for at least 30 days in the absence of a concurrent illness or condition other than HIV infection that could explain fi ndings (e.g., tuberculosis, cryptosporidiosis, or other specifi c enteritis). 17 We were mainly focused on weight loss due to tuberculosis.
RESULTS
The mean age of the individuals was 33.7 years which ranged from 2 years to 67 years. Around one-third were males. Almost 40% of males and 25.3% of females had TB co-infection. In the study sample, 72.8% were married, 8% were unmarried, 14.1% were single, 5.1% was widow/widower. Of the total sample 65.5% were IDU and 34.5% were non-IDU. Majority of them (94.2%) were receiving ART and 5.8% were to start ART or not taking ART. The study revealed that 36.1% persons were coinfected with tuberculosis. About 5.75% had HBV and 41.53% had HCV infection (Table 1) .
There was signifi cant association of TB coinfection among male compared to females (Figure 1 ).
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associated among them (P=0.001). But after one year of starting ART, there was no signifi cant association on average CD4 count among the two groups. However, data shows a slight increment in average CD4 count among TB co-infected persons than not infected persons. Similar association was observed after 1.5 years, 2 years, 2.5 years, 3 years and 3.5 years. * Signifi cant value **After one year of having taken ART, the mean CD4 count became more in TB co-infected individuals compared to those who had no TB coinfection. Then subsequently the mean CD4 count was always at higher level among those who had TB compared to those who hadn't. 
DISCUSSION
The present study estimated the prevalence of TB co-infection among HIV positive individuals to be 36.1 % in context Nepal which is consistent with worldwide statistics. 1 There was signifi cant association of TB co-infection among male compared to females (OR=1.95, CI=1.06-2.37, P=0.021). Among TB co-infected cases, fever was the commonest clinical feature, followed by weight loss and cough. A night sweat, which was considered as one of the constitutional symptoms didn't have dominant fi gure in this study.
Other symptoms among the cases were chronic diarrhea (31 %), headache (29.2%), easy fatigue (21.2%) and night sweats (4.4%). However only fever, weight loss and cough were the signifi cant symptom associated with TB co-infection. The clinical presentation of TB in HIV infection is affected by the degree of underlying immune suppression. 5 Our study is consistent with this fact because we found that the mean CD 4 counts of the patients co-infected with TB being much less than in those who were not. Of all symptoms, weight loss can be of utmost important. Studies have repeatedly documented that the existence and magnitude of weight loss predict morbidity and mortality. 18, 19 Correlations have been established between high HIV viral load, low CD4 cell counts, and weight loss. In HAART experienced patients with suppressed plasma viral load, weight loss has been attributed to the persistence of HIV in peripheral blood monocytes and macrophages. The persistence of HIV leads to excessive cytokine activation and dysregulation, and this in turn triggers various metabolic abnormalities that lead to weight loss such as increase in resting energy expenditure, proteolysis, and hypercatabolism. 17 A study reported that as little as 5% of weight loss over 4 months was associated with decreased survival. 20 We also found that the majority of the patients lived with family .i.e. the major bulk of HIV infected patients had good support from the family as 61.7% lived with their family. Had there been no co-operation from the family, they would not be staying along with the family members. Stay in rehabilitation center counted for second largest population (21.4%). It was due to the reason that they wanted to live with individuals having same disease so that they could share their feelings and learn more about the disease. Also, a good number of populations lived alone (16.3%) which may be indicative of lack of social support. Environmental
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social determinants, such as housing conditions, social networks, and social support, are also key drivers for HIV/AIDS, viral hepatitis, STDs, and TB. Kidder et al. conducted a study among housed and homeless individuals with HIV/AIDS and found that homeless people with HIV/AIDS had poorer health status, were less adherent to medication regimens, and were more likely to be uninsured and to have been hospitalized. 21 There is effect of tuberculosis on mortality in HIV positive people. A Meta-Analysis shows that people living with HIV (PLWH) with TB face an approximately two times higher risk of death from all causes compared to PLWH without TB. The increased hazard of mortality implies that PLWH with TB die earlier compared to PLWH without TB. 22 In our study more than one third (36.1%) persons were co-infected with TB.
Our study revealed that nearly two third (64.6%) of TB infected patients had pulmonary TB followed by gland TB (25.7%) and spinal TB (5.3%). This supports that prime concern of co-infection of TB in HIV positive individuals is that of pulmonary TB followed by gland TB. At CD4+ cell counts greater than 350/μL, TB disease is most often limited to the lungs, histopathologic results are similar to those in HIV-seronegative patients (i.e., granuloma with or without caseation), and extrapulmonary involvement, when present, usually is nodal or pleural (Burman and Jones, Semin Respir Infect, 2003). In advanced HIV infection, pulmonary involvement is still the most common TB presentation; however, extra-pulmonary involvement is observed in approximately 70% of patients with CD4+ cell counts less than 100/ μL, and up to 50% of those with CD4+ cell counts greater than 50/μL will have positive TB blood cultures. 5 With proper treatment, a person with infectious tuberculosis very quickly becomes non-infectious -probably most often in less than two weeksand so can no longer transmit infection to others. 7 Highly active antiretroviral therapy (HAART) improves the immune function and decreases morbidity, mortality and opportunistic infections in HIV-infected patients. HAART improves immune function by suppressing HIV viral replication and increasing CD4+ T-cell counts. 23 With respect to our study-before starting ART, the average CD4 count was found to be signifi cantly less among TB-HIV co-infected patients compared to those who didn't have TB co-infection. Similarly, after six months, the mean CD4 count was signifi cantly associated among the two groups. After one year of having taken ART, the mean CD4 count became more in TB co-infected individuals compared to those who had no TB co-infection. Then subsequently the mean CD4 count was always at higher level among those who had TB compared to those who hadn't.
The risk of TB following M. tuberculosis infection is determined mainly by the individual's immune status (and hence HIV infection is a potent risk factor for tuberculosis). 6 It was found that the mean CD 4 count was in increasing pattern without any turn down for three and half years among TB coinfected individuals, but the group which were TB free had fl uctuating mean CD4 count. This shows that there is marked increase in CD4 count in TB co-infected individuals despite lower initial CD4 count before starting ART. But after three and half years the variation is somewhat similar. Studies of the kinetics of CD4+ count response post-HAART indicate that the CD4+ count increases rapidly during the fi rst 3-6 months, in part due to release of memory T-cells from lymphoid tissue, and then increases slowly during the next 3-4 years, refl ecting reconstitution of the immune system. The magnitude of CD4+ recovery may depend on a variety of factors, including maintenance of virologic suppression, age, and CD4+ count at HAART initiation.
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There are no validated markers to differentiate those who will have a more robust CD4 response to ARV from those who will not. 24 Antiretroviral drug concentrations are among the most important determinants of clinical response to a drug accounting for both toxicity and effi cacy. 25 We also tried to see pattern of change of mean CD 4 count among different type of TB co-infection. Those people who had pulmonary TB, had mean CD4 count of 157.86 just before starting ART compared to mean CD4 count of 214.21 in the individuals who had TB of gland and 127.17 in the individuals who had TB of spine. The mean CD 4 count of 157.86 for pulmonary TB is quite low as compared to other similar studies. It could have been so because there was also hepatitis infection among the volunteers of the study. Among TB co-infected individuals, 6.2% had HBV alone, 38.9% had HCV alone and 2.7% had both HBV and HCV infection. Another explanation could be that TB facilitates HIV viral replication to a greater extent in the earlier stages of HIV infection than during advanced illness, when viral replication is already at its peak. 26 We found that the mean CD4 count was in rising pattern without any decline for three and half years among the population with pulmonary TB, but the ones having TB of gland also had rising pattern of mean CD4 count but only for two years. Then the mean CD4 count had falling pattern till three and half years. The mass of people having TB of spine had fl uctuating pattern of mean CD4 count as shown in fi gure 3. The question of whether those initiating HAART will continue to increase their CD4+ count after 4-5 years or will plateau has been debated in the literature, and remains unclear. Some studies have suggested that normalization of CD4+ counts in HIV-infected persons can be achieved if viral suppression with HAART can be maintained for a suffi ciently long period of time.
11 Several factors such as age, ethnicity, body weight and patients' immune status may infl uence antiretroviral drug concentrations. 25 In our study, those who were taking ART had mean CD4 count of 180.16 just before starting ART compared to mean CD4 count of 447.78 in the individuals who were not taking ART. We found that the mean CD4 count was in increasing pattern without any decline for two and half years among the population taking ART whereby the mean CD4 count was 391.98. But in succeeding six months' duration, the mean CD4 count decreased to 379.39. In subsequent six month the mean CD4 count increased to 410.28. The mass not taking ART had falling pattern of mean CD4 count for one and half year (Table 3) . In one study, after > 5 years on HAART, patients with viral suppression who started at <200 cells/ mm3 had an adjusted annual increase of 32 cells/ mm3, attaining an average CD4+ count of 497 cells/mm3. Another study statistically estimating the CD4+ trajectory concluded that those starting HAART at <200 CD4+ cells who remained on therapy would continue to increase through 7 years, although 25% still had <350 cells at 7 years. One small study of 16 patients followed for up to 10 years with strict viral control based on HIV RNA detection using ultrasensitive techniques showed continued positive increases in CD4 + counts, although this study represented a small group of highly selected patients.
On the other hand, other studies report that the average CD4+ count may level off after 4-6 years following HAART initiation, even among patients with viral suppression. Given this leveling off, many patients who start at lower CD4+ counts, even after years on HAART with early CD4+ increases, may fail to reach a normal CD 4 + threshold. In one study of those with sustained viral suppression who started HAART at <200 CD4+ cells/mm3, after 6 years only 42% had > 500 CD4+ cells/mm3, and only 12% had >750 cells/mm3. In another study, 44% of those starting therapy with a CD4+ count <100 cells/mm3 and 25% of those starting HAART with a CD4+ count of 100-200 cells were unable to achieve a CD4+ cell count >500 cells/mm3 over a mean follow-up of seven years, and many did not reach this threshold by year 10.
Antiretroviral therapy improves survival in HIVpositive patients. In addition, antiretroviral therapy reduces TB rates by up to 90% at an individual level, by 60% at a population level and it reduces TB recurrence rates by 50%. ART should be initiated for all people living with HIV with active TB disease irrespective of CD4 cell count. TB treatment should be started fi rst, followed by ART as soon as possible and within the fi rst 8 weeks of starting TB treatment. 27 Despite several explanations, the most important aspect is the survival the HIV infected individuals. Death rates in HIV-positive individuals remain elevated compared to those in the general population and it is believed that HIV may play a role in the development of several serious non-AIDS conditions. Thus, combination ART may have a greater positive impact on the health of HIV-positive individuals than anticipated, which may now justify its earlier use. 28 The dramatic scale-up of ART in resource-limited settings has brought not only TB treatment but also prevention of TB in HIV-infected persons to the forefront. TB prevention strategies with known effi cacy include rapid identifi cation and treatment of active TB cases (in source patients), infection-control measures to reduce nosocomial transmission of TB and ART to reduce the incidence of TB among HIV-infected patients. Research priorities in TB prevention center on adapting and improving these known strategies for HIV infection in resource-limited settings.
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CONCLUSION
TB and HIV co-infection is an emerging medical issue in Nepal. The prevalence of TB coinfection among HIV cases is found to be 36.1%. Consideration of TB need to be made while caring patients with HIV infection and vice versa. Timely given ART can be of utmost signifi cance so it should be initiated when CD4 cell count falls below the cut off value. Preventive, promotive and curative aspects of TB and HIV should be undertaken hand in hand so that both of these entities are addressed simultaneously.
